Pro Dex Inc (PDEX) · Oct 29, 2026 · Earnings
Beat — Diluted EPS $0.92 vs ~$0.67 consensus; revenue $20.56M vs ~$20.40M
Pro-Dex earnings beat Q1 revenue and EPS expectations as next-generation handpiece sales drove growth, while investment gains normalized.
Pro-Dex is a surgical-instrument manufacturer using its APM subsidiary to add aerospace and defense machining while ramping a next-generation handpiece for its largest medical-device customer; APM became part of the business in fiscal 2026. The quarter cleared the market’s bar. Published Q1 expectations were roughly $20.40 million of revenue and $0.67 of EPS; Pro-Dex delivered $20.56 million and $0.92, respectively.
| Q1 FY2027 | Q1 FY2026 | Consensus | |
|---|---|---|---|
| Net sales (Financial Data) | $20.56M | $18.53M | ~$20.40M |
| Diluted EPS (Financial Data) | $0.92 | $1.40 | ~$0.67 |
| Gross margin (Results discussion) | 33% | 29% | |
| Operating income (Results discussion) | $3.5M | $3.1M | |
| Operating expenses (Financial Data) | $3.34M | $2.26M |
The core operating story improved more than the headline net income suggests. Revenue rose 11% to $20.6 million, led by a $3.3 million increase in medical-device revenue, including $1.8 million from the next-generation handpiece, while legacy-handpiece repairs fell $1.7 million; APM added another $511,000 of revenue.
Mix drove a meaningful margin gain despite heavier investment. Gross margin expanded four percentage points to 33%, but operating expenses jumped 48% as engineering, personnel, and APM-related costs rose. Even after that spending, operating income increased 13% to $3.5 million. 〔0〕
The lower net income is mostly a distorted comparison, not an operating reversal. Diluted EPS fell to $0.92 from $1.40 because the year-ago quarter included a $3.3 million unrealized investment gain, versus just $73,000 this quarter. The cleaner operating measures—revenue, gross margin, and operating income—each moved higher.
The next strategic proof point is still ahead. Management expects to ship Monogram validation units later in fiscal 2027, which could provide evidence that the newer customer program is progressing beyond the current handpiece ramp. 〔1〕
Bottom line: This was a genuine earnings beat with stronger underlying operations than the year-ago EPS comparison implies. The main improvement is that next-generation medical-device demand and better mix are beginning to offset legacy repair declines, though higher spending bears watching as APM and engineering investments scale.
Monogram validation-unit shipments later in fiscal 2027
A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.
A buy-side analyst on every ticker — the whole market decoded the second it moves, before it's a headline. Free gives you a taste. Pro takes the cap off and opens the full read on every company.
by Signing in NOW, claim your FREE 14-day Pro trial!